Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2561]

Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2...

Dr Mabel Mardones - Rocky Mountain Cancer Centers, Denver, USA

Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer ( Dr Mabel Mardones - Rocky Mountain Cancer Centers, Denver, USA )

Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival...

Dr Bjorn Henning Gronberg - Norwegian University of Science and Technology...

Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC ( Dr Bjorn Henning Gronberg - Norwegian University of Science and Technology, Trondheim, Norway )

Amivantamab plus pembrolizumab and carboplatin in R/M HNSCC: Evaluating...

Dr Barbara Burtness - Yale School of Medicine, New Haven, USA

Amivantamab plus pembrolizumab and carboplatin in R/M HNSCC: Evaluating improved response and survival vs chemo ( Dr Barbara Burtness - Yale School of Medicine, New Haven, USA )

Talazoparib plus enzalutamide improves radiographic progression-free survival...

Dr Neeraj Agarwal - University of Utah, Salt Lake City, USA

Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC ( Dr Neeraj Agarwal - University of Utah, Salt Lake City, USA )

Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

2: Managing EGFR inhibitor side effects in NSCLC - Skin toxicity impact...

Helena Ullgren, Rachel Powell, Patrick Jahn and Elin Backman Stålnacke

2: Managing EGFR inhibitor side effects in NSCLC - Skin toxicity impact, adherence challenges, and nursing management ( Helena Ullgren, Rachel Powell, Patrick Jahn and Elin Backman Stålnacke )

3: MDT collaboration in NSCLC - Aligning oncologists, nurses, and patients to...

Helena Ullgren, Elin Backman Stålnacke, Dr Pascale Tomasini and Gini Harrison

3: MDT collaboration in NSCLC - Aligning oncologists, nurses, and patients to enhance EGFR inhibitor treatment pathways and supportive care ( Helena Ullgren, Elin Backman Stålnacke, Dr Pascale Tomasini and Gini Harrison )

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk...

Dr Matteo S. Carlino - Westmead Hospital and Melanoma Institute Australia...

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma ( Dr Matteo S. Carlino - Westmead Hospital and Melanoma Institute Australia, Sydney, Australia )

ASCO 2026: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2026: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Velzatinib demonstrates broad activity across KIT mutations in advanced...

Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston...

Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours ( Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston, USA )

Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type...

Dr Ramón Salazar - The University of Barcelona, Barcelona, Spain

Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer ( Dr Ramón Salazar - The University of Barcelona, Barcelona, Spain )

More from ecancer